Kimball Electronics (KE) Q4 2026: Medical Segment Drives 10% Annual Growth Amid Portfolio Rebalancing
Kimball Electronics ended fiscal 2026 with stabilizing sales and a strategic pivot toward medical contract development and manufacturing services. The company’s strengthened balance sheet enables investments supporting organic growth and the accretive Helvoet acquisition, positioning medical to exceed one-third of total sales in fiscal 2027.
Summary
- Portfolio Realignment Accelerates: Medical vertical outpaced automotive and industrial, driving company-wide growth momentum.
- Strategic Capital Deployment: Enhanced balance sheet supports organic expansion and integration of Helvoet acquisition.
- Operational Efficiency Gains: Improved cash conversion and disciplined working capital management underpin financial resilience.
Business Overview
Kimball Electronics is a global Electronics Manufacturing Services (EMS) and Contract Development and Manufacturing Organization (CDMO) provider serving diversified vertical markets including medical, automotive, and industrial. The company generates revenue by manufacturing electronic components and assemblies, with a growing emphasis on medical CDMO services that combine product development and manufacturing capabilities. Its operations span North America, Europe, and Asia, with key segments contributing variably to total sales.
Performance Analysis
In the fourth quarter of fiscal 2026, Kimball Electronics reported net sales of $371.6 million, reflecting a 2% year-over-year decline but a 5% sequential increase, driven by gains across all vertical markets. The medical segment, accounting for 29% of sales, posted a 1% year-over-year increase and sustained growth through all quarters of the fiscal year, culminating in over 10% annual growth after adjusting for prior-year inventory consignment effects. Automotive and industrial verticals faced headwinds with sales declining 3% and 5% respectively, primarily due to softer demand in North America and specific product categories such as EV programs and HVAC systems.
Gross margin improved by 90 basis points to 8.9%, aided by favorable product mix and partially offset by ramp-up costs at the new medical CDMO facility in Indianapolis. Adjusted operating income margin slightly contracted to 4.9%, reflecting increased investments in personnel and IT infrastructure to support growth initiatives. The company generated $42.4 million in operating cash flow, marking its tenth consecutive quarter of positive cash generation and contributing to a 21% year-over-year reduction in debt to $116.6 million, the lowest in over four years. Cash conversion days improved to 82, the best in 17 quarters, underscoring effective working capital management despite anticipated supply chain inventory pressures in fiscal 2027.
- Segment Growth Divergence: Medical’s consistent double-digit growth contrasts with stabilization trends in automotive and industrial.
- Margin Dynamics: Mix-driven gross margin gains offset by strategic investments in future capabilities.
- Balance Sheet Strength: Debt reduction and cash generation provide financial flexibility for growth and acquisitions.
This financial profile reflects Kimball’s transition toward a more balanced portfolio and positions the company for profitable growth in fiscal 2027.
Executive Commentary
"Our guidance for fiscal 2027 is highlighted by organic sales growth and the accretive impact from Helvoet. We are expecting Medical to continue to outpace the other two verticals and represent more than one-third of total company sales in the fiscal year, which is in line with our objective to balance the portfolio across the markets we serve."
Rick Phillips, Chief Executive Officer
"As a CFO who takes great pride in the condition of our balance sheet, we exited the fiscal year in a position of strength, with plenty of dry powder in the form of borrowing capacity and available cash to strategically invest. Our guidance for fiscal 2027 projects a return to top line growth and we will be leveraging the balance sheet to support those efforts."
Jana Croom, Chief Financial Officer
Strategic Positioning
1. Medical CDMO Expansion as Growth Engine
Kimball is accelerating its shift toward medical CDMO services, integrating Helvoet Polymer Technologies to expand capabilities and geographic reach. The medical vertical now represents nearly 30% of sales and is projected to surpass one-third in fiscal 2027. The new Indianapolis facility buildout complements this strategy, though initial production ramp is gradual with full transition expected over 18 months. The company is leveraging cross-selling opportunities and co-development capabilities to deepen customer relationships and diversify product categories including surgical devices, diagnostics, and drug delivery.
2. Portfolio Diversification and Stabilization
While medical drives growth, automotive and industrial segments are stabilizing after multi-year declines. Automotive sales declined 7% in fiscal 2026 due to lower EV demand, with regional disparities showing strength in European steering and braking programs offsetting North American softness. Industrial sales contracted 5%, mainly from HVAC weakness in North America, partially offset by smart meter recovery in Europe. This balanced portfolio approach mitigates cyclicality and positions Kimball for steady revenue streams.
3. Financial Discipline and Capital Allocation
Kimball’s improved cash conversion days and disciplined working capital management have enabled significant debt reduction and share repurchases. The company plans capital expenditures of $50 to $60 million in fiscal 2027, focusing on facility investments and new program support. It maintains a leverage target between 1.5 and 2 times EBITDA to preserve flexibility for organic growth and opportunistic acquisitions, continuing a share repurchase program with $24.4 million authorization remaining.
4. Integration and Synergy Realization of Helvoet Acquisition
Post-acquisition integration is progressing on schedule with active collaboration between teams to unlock revenue synergies. Customer retention remains strong, and the expanded footprint in Europe, India, and the U.S. enhances competitive positioning. Currency translation impacts temper near-term revenue growth from Helvoet, but management expects 8% top-line growth from the acquisition in fiscal 2027, with more substantial synergy benefits materializing over time.
5. Operational Efficiency Amid Growth Investments
Despite investments in the medical ramp and IT infrastructure, Kimball improved gross margin and operating income margins remained stable. The company anticipates some working capital pressure in fiscal 2027 due to customer inventory demands but expects to manage these efficiently. The disciplined operational approach supports the strategic pivot without sacrificing financial health.
Key Considerations
Kimball Electronics’ fiscal 2026 results underscore a pivotal transition toward a more balanced and growth-oriented business model. Investors should consider the following:
- Medical Segment Growth Sustainability: Continued momentum in diverse medical product categories supports organic growth targets but depends on successful facility ramp and integration.
- Automotive and Industrial Recovery Trajectory: Stabilization in automotive and industrial segments provides a base but remains sensitive to macroeconomic and regulatory factors, particularly EV demand.
- Capital Allocation Balance: Management is balancing investments in organic growth, acquisition integration, and shareholder returns while maintaining financial flexibility.
- Working Capital Dynamics: Anticipated inventory build demands in fiscal 2027 may modestly increase cash conversion days, requiring close management.
- Currency and Geopolitical Risks: Exposure to multiple currencies and global operations introduces translation and geopolitical uncertainties impacting near-term results.
Risks
Risks include potential delays in ramping the Indianapolis medical facility, integration challenges with Helvoet, and continued softness in automotive EV volumes. Supply chain disruptions and currency fluctuations may also pressure margins and working capital. The company’s forward-looking statements acknowledge uncertainties including global economic conditions and regulatory changes that could materially affect performance.
Forward Outlook
For fiscal 2027, Kimball Electronics guided to:
- Net sales between $1.535 billion and $1.56 billion, representing 7% to 9% growth over fiscal 2026.
- Organic sales growth of 3% to 5%, with medical expected to grow in the high single to low double-digit range.
- Adjusted operating income margin of 4.4% to 4.7% of net sales.
- Capital expenditures of $50 million to $60 million focused on growth initiatives.
Management highlighted that the Indianapolis facility ramp’s dilutive impact is offset by Helvoet’s accretive contribution, with revenue synergies expected to develop as the CDMO strategy unfolds. Revenue distribution is anticipated to be balanced across quarters.
Takeaways
Kimball Electronics is navigating a strategic inflection point, shifting from legacy automotive and industrial reliance toward a more diversified portfolio anchored by medical CDMO growth. The company’s strengthened financial position provides a foundation for organic expansion and acquisition integration, though execution risks remain in facility ramp and market dynamics.
- Medical Segment as Growth Catalyst: Sustained double-digit medical growth and Helvoet acquisition integration are central to achieving fiscal 2027 targets and portfolio balance.
- Operational and Financial Discipline: Improved cash conversion and debt reduction underpin resilience, enabling continued investments and shareholder returns.
- Execution and Market Risks: Investors should monitor ramp progress, automotive demand recovery, and working capital trends as key indicators of future performance.
Conclusion
Kimball Electronics’ fiscal 2026 results reflect a successful transition phase with a clear strategic pivot toward medical CDMO services driving growth and portfolio diversification. The company’s strong balance sheet and disciplined execution position it well for profitable expansion in fiscal 2027, though execution and market uncertainties warrant close attention.
Industry Read-Through
Kimball’s emphasis on medical CDMO growth amid automotive and industrial stabilization mirrors broader EMS industry trends prioritizing high-value, regulated markets with stronger secular growth. The integration of specialty acquisitions like Helvoet highlights the increasing importance of geographic and capability expansion to meet customer demands for end-to-end solutions. Other EMS providers should note the strategic value of balancing legacy manufacturing with innovation-driven segments and maintaining financial flexibility to capitalize on inorganic growth opportunities. Working capital discipline and supply chain resilience remain critical as industry participants navigate evolving global trade and regulatory environments.